These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25336693)

  • 1. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
    Shapiro GI; Kwak E; Dezube BJ; Yule M; Ayrton J; Lyons J; Mahadevan D
    Clin Cancer Res; 2015 Jan; 21(1):87-97. PubMed ID: 25336693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.
    Do K; Speranza G; Chang LC; Polley EC; Bishop R; Zhu W; Trepel JB; Lee S; Lee MJ; Kinders RJ; Phillips L; Collins J; Lyons J; Jeong W; Antony R; Chen AP; Neckers L; Doroshow JH; Kummar S
    Invest New Drugs; 2015 Aug; 33(4):921-30. PubMed ID: 26082332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
    Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
    Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
    Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M
    Mol Cancer Ther; 2019 Mar; 18(3):531-540. PubMed ID: 30679388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
    Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
    Rajan A; Kelly RJ; Trepel JB; Kim YS; Alarcon SV; Kummar S; Gutierrez M; Crandon S; Zein WM; Jain L; Mannargudi B; Figg WD; Houk BE; Shnaidman M; Brega N; Giaccone G
    Clin Cancer Res; 2011 Nov; 17(21):6831-9. PubMed ID: 21908572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
    Spreafico A; Delord JP; De Mattos-Arruda L; Berge Y; Rodon J; Cottura E; Bedard PL; Akimov M; Lu H; Pain S; Kaag A; Siu LL; Cortes J
    Br J Cancer; 2015 Feb; 112(4):650-9. PubMed ID: 25625276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors.
    Chang SS
    J Urol; 2016 Jul; 196(1):61. PubMed ID: 27321499
    [No Abstract]   [Full Text] [Related]  

  • 11. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.
    Sessa C; Shapiro GI; Bhalla KN; Britten C; Jacks KS; Mita M; Papadimitrakopoulou V; Pluard T; Samuel TA; Akimov M; Quadt C; Fernandez-Ibarra C; Lu H; Bailey S; Chica S; Banerji U
    Clin Cancer Res; 2013 Jul; 19(13):3671-80. PubMed ID: 23757357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.
    Spiegelberg D; Dascalu A; Mortensen AC; Abramenkovs A; Kuku G; Nestor M; Stenerlöw B
    Oncotarget; 2015 Nov; 6(34):35652-66. PubMed ID: 26452257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.
    Bauer S; Hilger RA; Mühlenberg T; Grabellus F; Nagarajah J; Hoiczyk M; Reichardt A; Ahrens M; Reichardt P; Grunewald S; Scheulen ME; Pustowka A; Bock E; Schuler M; Pink D
    Br J Cancer; 2014 Mar; 110(5):1155-62. PubMed ID: 24434430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
    Pacey S; Wilson RH; Walton M; Eatock MM; Hardcastle A; Zetterlund A; Arkenau HT; Moreno-Farre J; Banerji U; Roels B; Peachey H; Aherne W; de Bono JS; Raynaud F; Workman P; Judson I
    Clin Cancer Res; 2011 Mar; 17(6):1561-70. PubMed ID: 21278242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
    Goldman JW; Raju RN; Gordon GA; El-Hariry I; Teofilivici F; Vukovic VM; Bradley R; Karol MD; Chen Y; Guo W; Inoue T; Rosen LS
    BMC Cancer; 2013 Mar; 13():152. PubMed ID: 23530663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
    Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
    Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
    Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
    Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
    Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
    Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
    Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.